WHITEPAPERS

In recent years, nitrosamine impurities have emerged as one of the most significant quality and safety challenges facing the global pharmaceutical industry.

Unlocking new frontiers in pharmaceutical innovation

Intranasal drug delivery is evolving from a simple convenience into a strategic route with broader therapeutic potential. But delivering a drug through the nose is not as straightforward as it seems. It demands precise coordination between formulation, device, and biology. This article breaks down what it really takes to develop reliable, scalable nasal spray products.

A tablet is often judged by its final form. In development, however, its success is decided much earlier: in the behaviour of the API, the choice of excipients, the stability profile, the dissolution pathway, and the way the formulation performs at scale. Each decision shapes whether the product can remain safe, effective, manufacturable, and market-ready. That is why formulation development is a scientific journey that must be built carefully, tested rigorously, and never rushed.

What happens when a formulation that performs flawlessly in a 5-litre lab mixer is scaled up to a 500-litre production vessel—and <br>why is this delicate transition one of the most critical phases in pharmaceutical development that demands closer attention?